Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 455 matching drugs for CASP8 — including drugs targeting any of its 125 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
bryostatin 1, paclitaxel CASP8 Direct 2
paclitaxel, bryostatin 1 CASP8 Direct 1
binimetinib and encorafenib BRAF SSL via BRAF yes 1
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab RAF1 SSL via RAF1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab VEGFA SSL via VEGFA 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) RAF1 SSL via RAF1 4
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine VEGFA SSL via VEGFA 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CDK4 SSL via CDK4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FYN SSL via FYN 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib LYN SSL via LYN 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib RAF1 SSL via RAF1 3
bevacizumab VEGFA SSL via VEGFA 3
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus MTOR SSL via MTOR 3
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin VEGFA SSL via VEGFA 2
5fu, nab-paclitaxel, bevacizumab, calcium leucovorin, oxaliplatin VEGFA SSL via VEGFA 2
abemaciclib CDK4 SSL via CDK4 yes 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel RAF1 SSL via RAF1 2
alvocidib, paclitaxel CDK4 SSL via CDK4 2
alvocidib, paclitaxel CDK9 SSL via CDK9 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment FYN SSL via FYN 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment LYN SSL via LYN 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment VEGFA SSL via VEGFA 2
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis VEGFA SSL via VEGFA 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib CDK4 SSL via CDK4 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study MTOR SSL via MTOR 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab CDK4 SSL via CDK4 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib JAK2 SSL via JAK2 2
everolimus MTOR SSL via MTOR yes 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC2 SSL via HDAC2 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib JAK2 SSL via JAK2 2
ksq-001ex, interleukin-2, cyclophosphamide, fludarabine POLA1 SSL via POLA1 2
motexafin gadolinium, radiation therapy RRM2 SSL via RRM2 2
nintedanib LYN SSL via LYN 2
nintedanib, pembrolizumab LYN SSL via LYN 2
osimertinib, bevacizumab, osimertinib VEGFA SSL via VEGFA 2
palbociclib CDK4 SSL via CDK4 yes 2
pd-1 inhibitor, bevacizumab, carboplatin, cisplatin, pemtrexed VEGFA SSL via VEGFA 2
pembrolizumab, guadecitabine, mocetinostat HDAC2 SSL via HDAC2 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin VEGFA SSL via VEGFA 2
pemetrexed, bevacizumab VEGFA SSL via VEGFA 2
pharmacological study, romidepsin HDAC2 SSL via HDAC2 2
regorafenib RAF1 SSL via RAF1 yes 2
regorafenib, laboratory biomarker analysis RAF1 SSL via RAF1 2
sorafenib, administered orally, ct/mri RAF1 SSL via RAF1 2
temsirolimus MTOR SSL via MTOR 2
temsirolimus, laboratory biomarker analysis MTOR SSL via MTOR 2
tucidinostat (chidamide), pd-1 inhibitor (toripalimab), bevacizumab VEGFA SSL via VEGFA 2
3-dimensional conformal radiation therapy, bevacizumab, cisplatin, fluorouracil, intensity-modulated radiation therapy VEGFA SSL via VEGFA 1
3-dimensional conformal radiation therapy, bevacizumab, intensity-modulated radiation therapy, laboratory biomarker analysis, placebo, quality-of-life assessment, temozolomide VEGFA SSL via VEGFA 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat HDAC2 SSL via HDAC2 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat HDAC2 SSL via HDAC2 1
3-dimensional conformal radiation therapy, motexafin gadolinium, temozolomide RRM2 SSL via RRM2 1
abemaciclib, abemaciclib CDK4 SSL via CDK4 1
abemaciclib, bevacizumab CDK4 SSL via CDK4 1
abemaciclib, bevacizumab VEGFA SSL via VEGFA 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf CDK4 SSL via CDK4 1
abemaciclib, ly3023414, gemcitabine, capecitabine CDK4 SSL via CDK4 1
abemaciclib, ly3214996 CDK4 SSL via CDK4 1
abemaciclib, surgery CDK4 SSL via CDK4 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy HDAC2 SSL via HDAC2 1
adriamycin, cyclophosphamide, vindesine, valproic acid HDAC2 SSL via HDAC2 1
aee788, everolimus MTOR SSL via MTOR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib CDK4 SSL via CDK4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib FYN SSL via FYN 1
afatinib, dasatinib, palbociclib, everolimus, olaparib LYN SSL via LYN 1
afatinib, dasatinib, palbociclib, everolimus, olaparib MTOR SSL via MTOR 1
aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes POLA1 SSL via POLA1 1
alpelisib, everolimus, exemestane MTOR SSL via MTOR 1
alvocidib, docetaxel CDK4 SSL via CDK4 1
alvocidib, docetaxel CDK9 SSL via CDK9 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis CDK4 SSL via CDK4 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis CDK9 SSL via CDK9 1
amgen 386, bevacizumab VEGFA SSL via VEGFA 1
andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel VEGFA SSL via VEGFA 1
anetumab ravtansine, bevacizumab, paclitaxel VEGFA SSL via VEGFA 1
ang1005, bevacizumab VEGFA SSL via VEGFA 1
anti-endoglin chimeric monoclonal antibody trc105, bevacizumab, laboratory biomarker analysis, pharmacological study, quality-of-life assessment VEGFA SSL via VEGFA 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib CDK4 SSL via CDK4 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib MTOR SSL via MTOR 1
arsenic trioxide IKBKB SSL via IKBKB 1
arsenic trioxide, radiation therapy IKBKB SSL via IKBKB 1
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy IKBKB SSL via IKBKB 1
asc40 tablets, placebo tablets, bevacizumab VEGFA SSL via VEGFA 1
atezolizumab injection, bevacizumab, transarterial chemoembolization VEGFA SSL via VEGFA 1
atezolizumab, bevacizumab VEGFA SSL via VEGFA 1
atezolizumab, bevacizumab, laboratory biomarker analysis, pharmacological study VEGFA SSL via VEGFA 1
atorvastatin, temozolomide, radiotherapy HDAC2 SSL via HDAC2 1
autologous mesothelin-specific tcr-t cells, cyclophosphamide, fludarabine, bendamustine POLA1 SSL via POLA1 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab HDAC2 SSL via HDAC2 1
azd5335, saruparib (azd5305), bevacizumab, carboplatin VEGFA SSL via VEGFA 1
azd6244, dacarbazine, erlotinib, docetaxel, temsirolimus MTOR SSL via MTOR 1
bendamustine, biopsy, biospecimen collection, computed tomography, cyclophosphamide, echocardiography, fludarabine, leukapheresis, magnetic resonance imaging, multigated acquisition scan, positron emission tomography, t-cell receptor-engineered t-cells POLA1 SSL via POLA1 1
bevacizumab, bevacizumab VEGFA SSL via VEGFA 1
bevacizumab, biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, osimertinib VEGFA SSL via VEGFA 1
bevacizumab, biospecimen collection, computed tomography, electronic health record review, hypofractionated radiation therapy, magnetic resonance imaging, retifanlimab VEGFA SSL via VEGFA 1
bevacizumab, bkm120 VEGFA SSL via VEGFA 1
bevacizumab, capecitabine, gemcitabine hydrochloride VEGFA SSL via VEGFA 1
bevacizumab, capecitabine/oxaliplatin, fluorouracil/folinic acid/oxaliplatin, capecitabine, fluorouracil/folinic acid/irinotecan, fluorouracil +/- folinic acid VEGFA SSL via VEGFA 1
bevacizumab, carmustine VEGFA SSL via VEGFA 1
bevacizumab, cediranib maleate VEGFA SSL via VEGFA 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.